Kenvue Inc. (NYSE:KVUE) Given Consensus Recommendation of “Hold” by Analysts

Shares of Kenvue Inc. (NYSE:KVUE) have earned a consensus rating of “Hold” from the sixteen brokerages that are currently covering the company, Marketbeat reports. Twelve research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $19.3333.

A number of research firms recently issued reports on KVUE. Canaccord Genuity Group lifted their target price on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a report on Wednesday, February 18th. Citigroup lowered their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, April 15th. Argus raised Kenvue to a “hold” rating in a report on Friday, March 6th. Jefferies Financial Group lowered Kenvue from a “buy” rating to a “hold” rating and lowered their target price for the stock from $23.00 to $18.00 in a report on Friday, January 30th. Finally, UBS Group lowered their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Tuesday, April 7th.

Kenvue Price Performance

NYSE:KVUE opened at $17.09 on Friday. The business’s 50-day moving average price is $17.48 and its 200 day moving average price is $17.32. The firm has a market cap of $32.81 billion, a P/E ratio of 20.10, a PEG ratio of 1.30 and a beta of 0.55. Kenvue has a 52-week low of $14.02 and a 52-week high of $24.35. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.Kenvue’s revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.24 earnings per share. As a group, sell-side analysts predict that Kenvue will post 1.16 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th will be given a dividend of $0.2075 per share. The ex-dividend date of this dividend is Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.9%. Kenvue’s payout ratio is 97.65%.

Insider Activity

In other news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.59% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kenvue

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Montag A & Associates Inc. raised its position in shares of Kenvue by 6.3% during the first quarter. Montag A & Associates Inc. now owns 10,156 shares of the company’s stock worth $175,000 after purchasing an additional 600 shares during the period. Cornerstone Wealth Group LLC raised its position in shares of Kenvue by 5.9% during the first quarter. Cornerstone Wealth Group LLC now owns 10,810 shares of the company’s stock worth $187,000 after purchasing an additional 606 shares during the period. Physician Wealth Advisors Inc. raised its position in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares during the period. Mill Creek Capital Advisors LLC raised its position in shares of Kenvue by 0.6% during the fourth quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company’s stock worth $2,143,000 after purchasing an additional 701 shares during the period. Finally, B & T Capital Management DBA Alpha Capital Management raised its position in shares of Kenvue by 0.3% during the fourth quarter. B & T Capital Management DBA Alpha Capital Management now owns 234,664 shares of the company’s stock worth $4,048,000 after purchasing an additional 712 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.